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QUALITY IMPROVEMENT

Enhancing Immunization Rates in Two Urban Academic
Primary Care Clinics: A Before and After Assessment
Zeeshan Yacoob, MD, MPH,1,2 Christopher Cook, DO,2 Fabiana Kotovicz, MD,1,2 Jessica J.F. Kram, MPH,1,2,3
Marianne Klumph, MA,2,3 Marisa Stanley, MPH,5 Paul Hunter, MD,1,4 Dennis J. Baumgardner, MD1,2,3
University of Wisconsin School of Medicine and Public Health, Madison, WI; 2Department of Family Medicine,
Aurora UW Medical Group, Aurora Health Care, Milwaukee, WI; 3Center for Urban Population Health, Milwaukee, WI;
4
City of Milwaukee Health Department, Milwaukee, WI; 5Eau Claire City-County Health Department, Eau Claire, WI
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Purpose	Immunization rates in many cities in the United States remain suboptimal compared to Healthy People
2020 Goals and are lower than national averages. This study aimed to determine whether a lecturebased educational intervention targeted at nurses and medical assistants would improve vaccination
rates.
Methods	We conducted a quality improvement study in two urban academic family medicine clinics serving a
predominantly Medicaid patient population as well as a sizable proportion of refugees. The intervention
consisted of 3 lectures that were delivered to clinic nurses and medical assistants. Vaccinations in
1689 patients — 872 in the 3-month preintervention period, 817 in the 3-month postintervention
period — were analyzed.
Results

 ollowing the educational intervention, a statistically significant increase was seen only in human
F
papillomavirus vaccine immunization rates for 13–18-year-olds (from 90.7% [n=54] to 100% [n=45];
P=0.036). When the results were stratified by clinic, only 1 site showed statistically significant
increases in: pneumococcal polysaccharide vaccine (23-valent) for high-risk 19-to-64-year-olds (from
36.4% [n=154] to 47.8% [n=136]; P=0.049); Haemophilus influenzae type B vaccine for 2-month-to5-year-olds (from 91.1% [n=112] to 97.3% [n=111]; P=0.048); and meningococcal conjugate vaccine
(quadrivalent) for 13–18-year olds (from 85.2% [n=27] to 100% [n=26]; P=0.042). No increases were
seen for our study’s refugee patient population (n=171), and a significant decrease of the second-dose
measles, mumps, and rubella vaccine (P=0.036) occurred in this subcohort.

Conclusions	Ultimately, this quality improvement study demonstrated that educational interventions alone have a
limited impact on increasing immunization rates. (J Patient Cent Res Rev. 2020;7:47-56.)
Keywords	
education; vaccination; primary health care; quality improvement; refugees
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Moreover, refugee populations are at an increased risk
for vaccine-preventable diseases, as the vast majority
relocate from developing countries that lack basic
health services, are war-torn, or are impoverished.1-4
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While both reminder recalls and best practice advisories
in the past have shown a lot of promise in regards to
increasing immunization rates, they do not necessarily
prompt the clinician at the time of the visit.5,6 This is not
ideal, as individuals from disadvantaged communities
tend to have fewer interactions with the health care
system and are more likely to have fragmented care.7,8

any of the Healthy People 2020 goals focus
on increasing immunization rates among
high-risk populations. Unfortunately, with
2020 upon us, many rates remain suboptimal. In the
United States thousands of adults die every year from
diseases that could have been prevented by vaccines.1-3
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On average, primary care physicians address 3
problems per encounter, some of which consume the
majority of each encounter’s time.9 Therefore, help
from nurses and medical assistants (MAs) can be an
extremely valuable tool to increase vaccination rates.10
In past studies, when nurses and MAs have been trained
on specific preventive health care topics, including
vaccines, their measures have improved.11-14
By comparing age-appropriate and comorbidityspecific vaccination rates before and after an educational
intervention, our study aimed to determine whether
a lecture-based educational intervention targeted at
nurses and MAs would improve vaccination rates.

METHODS

This study was deemed non-human subjects research
(ie, quality improvement) by Aurora Health Care’s
institutional review board, thus oversight was waived.
Patient Population and Chart Review
Patients seen within a 3-month time period at one of
two urban academic family medicine clinics located in
a midwestern state were analyzed. The preintervention
group presented from July 1, 2017, to September
30, 2017; the postintervention group presented from
November 1, 2017, to January 31, 2018. A prestudy
analysis looking at the aggregate data of the number
and types of vaccines administered during each month
of the year showed that these two 3-month windows
were the most similar in regards to the average number
of vaccinations administered per visit and the types of
vaccines administered during those visits.
Any patient who had a clinical encounter with one
of 20 current postgraduate-year-two (PGY-2) and
postgraduate-year-three (PGY-3) family medicine
residents met inclusion criteria for the study. Patients
were selected randomly using the statistical software
R for each pre- and postintervention chart review.
After the random selection, patients whose last visit
within the 3-month time span was with one of the
study’s investigators were excluded. Before the
random selection of charts for the postintervention
group, patients included in the preintervention chart
review were excluded. This was done in order to avoid
counting a patient who had been vaccinated during
the preintervention period as being up-to-date in the
postintervention period (Figure 1).
48
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Figure 1. Study timeline and overview of the chart
selection process. PGY, postgraduate year.

To determine which vaccine was indicated based on
the patient’s age and medical comorbidities at the time
of the visit, an Excel spreadsheet was coded based on
the patient’s age and health risks. The encounter date
was the most recent date within the 3-month period on
which the patient was seen by a PGY-2 or PGY-3 family
medicine resident. This date was used to calculate the
patient’s age in order to determine age-specific vaccine
indications.
The coding for vaccine indications was based on the
“Recommended Immunization Schedule for Adults
Aged 19 Years or Older — United States, 2017” and
“Recommended Immunization Schedule for Children
and Adolescents Aged 18 Years or Younger — United
States, 2017,” both of which were released by the
Advisory Committee on Immunization Practices and
approved by the Centers for Disease Control and
Prevention (CDC).15,16 For the purpose of this study,
vaccines were determined to be up-to-date if the patient
had received the complete series for a specific vaccine
or if the patient had received the indicated vaccine
during their last clinic encounter per documentation in
the Wisconsin Immunization Registry or in our health
Quality Improvement

system’s electronic health record. Definitions for
high-risk populations requiring additional vaccines,
including patients defined by this study as refugees,
are given in Appendix A (p. 55).17-19 Abbreviations for
vaccines studied in this analysis are provided in Box 1.
For assurance of consistency, a random selection of
40% of the charts from both pre- and postintervention
groups were reviewed a second time by a third
investigator. For cases in which a discrepancy was
found for a vaccine indication, the study investigators
reviewed the chart together to reach a consensus. The
occurrence of a discrepancy was very uncommon,
and all charts that ultimately required 3-investigator
review were deemed to have been done correctly by
the primary reviewer.
Intervention
A case-based lecture series was developed based on
standard CDC vaccination recommendations. The
lecture series consisted of 3 lectures, each 45 minutes
in length, with the goal of addressing immunization
guidelines and identified barriers to vaccination. The
first lecture covered current vaccination statistics,
common misconceptions, and vaccine-preventable
diseases. The second lecture covered specific vaccine
indications based on age or risk. Lastly, the third
lecture covered additional specific vaccine indications,
immunization resources, practice recommendations,
and communication recommendations. One of the

Box 1. Abbreviations for Vaccines
DT
diphtheria and tetanus toxoids
DTaP	diphtheria and tetanus toxoids and
acellular pertussis
Hep A
hepatitis A
Hep B
hepatitis B
Hib
Haemophilus influenzae type B
HPV
human papillomavirus
IPV
inactivated poliovirus
MenACWY meningococcal conjugate, quadrivalent
MMR
measles, mumps, and rubella
PCV13
pneumococcal conjugate (13-valent)
PPSV23
pneumococcal polysaccharide (23-valent)
Rotavirus
rotavirus vaccine
Td
tetanus and diphtheria
Tdap
tetanus, diphtheria, and acellular pertussis
Varicella
varicella vaccine
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investigators, a medical student between his third and
fourth year of training, carried out the lectures.
For each clinic site, 3 dates during the month of
October 2017 were selected for the educational
intervention, in coordination with the clinic manager
for both clinics. An email containing the selected dates
and inviting all of the nurses and MAs at both sites,
with emphasis that participation in the intervention
was completely voluntary, was sent.
The intervention took place during the lunch hour. As
an incentive, participants were given a $5 gift card
and light snack for each educational session that they
attended. All nurses and MAs who attended the sessions
were given a quick reference guide (Appendix B, p.
56), created by the study investigators, which included
a list of common vaccine indications, the American
Academy of Pediatrics “Refusal to Vaccinate” form,
and the CDC’s 2015 Pneumococcal Vaccine Timing
for Adults handout.20,21
Statistical Analysis
Data analysis was conducted using Minitab® statistical
software (Minitab, LLC, State College, PA) and Excel
(Microsoft Corp., Redmond, WA). All continuous
variables were summarized using descriptive statistics,
including number (n), mean, standard deviation (SD),
median, maximum, and minimum. Analysis of variance
(ANOVA) was used for multivariate modeling. Results
were considered significantly different if the p-value
was less than or equal to 0.05.

RESULTS

Vaccinations were reviewed for 1689 randomly
selected patients (872 preintervention, 817
postintervention) who met the inclusion criteria
(Figure 1). At Clinic 1, all 6 nurses and MAs who were
invited attended all 3 education sessions. At Clinic 2,
out of the 13 participants who were invited, 5 attended
all 3 sessions, 4 attended 2 sessions, and 4 attended 1
session. At both clinics, the vast majority of patients
were insured by Medicaid (n=1053, 62.3%), followed
by private insurance (n=312, 18.5%), and Medicare
(n=286, 16.9%). Overall, the sample population was
representative of the patient population at the clinics
in terms of age distribution (patients 19–64 years of
age: sample=54.9%; clinic population=52.3%), gender
(females: sample=60.7%; clinic population=60.0%),
www.aurora.org/jpcrr
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and primary language (English: sample=79.8%; clinic
population=81.7%).
The most common vaccination indication was heart/
lung disease, seen in 37.1% (n=626) of patients.
Additionally, 16.9% (n=285) of patients suffered from
diabetes and 12.7% (n=214) were determined to be
high risk for a sexually transmitted infection. Overall,
Clinic 1 was found to have a younger patient population
(<5 years old: 32.4% at Clinic 1 vs 9.5% at Clinic 2)
and more likely to self-identify as black, non-Hispanic
(70.9% at Clinic 1 vs 13.61% at Clinic 2) (Table 1).
When the results were stratified by clinic, only
Clinic 1 showed the following statistically significant
increases after the intervention: PPSV23 for highrisk 19–64-year-olds (from 36.4% [n=154] to 47.8%
[n=136]; P=0.049); Hib vaccine for 2-month-to-5year-olds (from 91.1% [n=112] to 97.3% [n=111];
P=0.048); and MenACWY for 13–18-year-olds (from
85.2% [n=27] to 100% [n=26]; P=0.042) (Tables 2 and
3). When the results from the two clinics were pooled,
HPV immunization rates for 13–18-year-olds also

were increased (from 90.7% [n=54] to 100% [n=45];
P=0.036). Furthermore, rates at both studied clinics
were higher across the board in comparison to national,
state, and city data (Tables 2 and 3).1,22,23
Refugee patients (n=171) comprised 10.1% of the total
study population. As shown in Table 4, no increases
were seen in vaccination rates within this subcohort,
and a significant decrease was seen for receiving
the second dose of the measles, mumps, and rubella
vaccine (MMR#2).

DISCUSSION

Our study found that a lecture-based educational
intervention for nurses and MAs did not significantly
increase immunization rates at both family medicine
clinics. While Clinic 1 did show some statistically
significant increases postintervention, Clinic 2 did not.
This may be due to the attendance rate of nurses and
MAs at Clinic 1 (100% of participants attended all 3
sessions) being dramatically higher than the attendance
rate at Clinic 2 (38% of participants attended all 3
sessions).

Table 1. Patient Demographics (N=1689)
Clinic 1

Clinic 2

Pre
n=449

Post
n=417

Total
n=866

Pre
n=423

Post
n=400

Total
n=823

Age, n (%)
0–4.99 years
5–18.99 years
19–64.99 years
>65 years

148 (33.0%)
52 (11.6%)
221 (49.2%)
28 (6.2%)

133 (31.9%)
53 (12.7%)
213 (51.1%)
18 (4.3%)

281 (32.4%)
105 (12.0%)
434 (50.1%)
46 (5.3%)

41 (9.7%)
66 (15.6%)
251 (59.3%)
65 (15.4%)

37 (9.3%)
54 (13.5%)
244 (61.0%)
65 (16.3%)

78 (9.5%)
120 (14.6%)
495 (60.6%)
130 (15.8%)

Sex, n (%)
Male
Female

182 (40.5%)
267 (59.5%)

159 (37.9%)
258 (61.6%)

341 (39.4%)
525 (60.6%)

173 (40.9%)
250 (59.1%)

150 (37.5%)
250 (62.5%)

323 (39.3%)
500 (60.8%)

Race/Ethnicity, n (%)
White, non-Hispanic
Hispanic
Black, non-Hispanic
Asian
Mixed/Other/Unknown

42 (9.4%)
41 (9.1%)
322 (71.7%)
30 (6.7%)
14 (3.1%)

49 (11.8%)
39 (9.4%)
292 (70.0%)
27 (6.5%)
10 (2.4%)

91 (10.5%)
80 (9.2%)
614 (70.9%)
57 (6.6%)
24 (2.8%)

136 (32.2%)
153 (36.2%)
55 (13.0%)
44 (10.4%)
35 (8.3%)

105 (26.3%)
162 (40.5%)
57 (14.3%)
43 (10.8%)
33 (8.3%)

241 (29.3%)
315 (38.3%)
112 (13.6%)
87 (10.6%)
68 (8.3%)

Refugee?, n (%)
Yes
No

36 (8.0%)
413 (92.0%)

28 (6.7%)
389 (93.3%)

64 (7.4%)
802 (92.6%)

60 (14.2%)
363 (85.8%)

47 (11.8%)
353 (88.3%)

107 (13.0%)
716 (87.0%)

Demographic

Post, postintervention; Pre, preintervention; Total, pre- and postintervention combined.
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Table 2. Adult Risk-Based Vaccine Rates Compared to National, State, and City Rates and Further Stratified
by Clinica

Clinic 1
National State City
Data1 Data22 Data22

Pre / Post
Up-to-Date

Clinic 2
Pre / Post
Up-to-Date

Pre

Post

P

19–64 y/o at high risk

42.1%
(n=309)

46.6%
(n=296)

0.261

23.0%

-

-

36.4% (n=154) /
47.8% (n=136)

0.049

47.7% (n=155) /
45.6% (n=160)

0.708

>65 y/o

83.3%
(n=90)

92.1%
(n=76)

0.091

63.6%

51.5%

43.5%

76.9% (n=26) /
87.5% (n=16)

0.409

85.9% (n=64) /
93.3% (n=60)

0.182

Diabetics

68.6%
(n=137)

76.4%
(n=148)

0.144

-

-

-

57.7% (n=52) /
71.2% (n=52)

0.155

75.3% (n=85) /
80.0% (n=95)

0.451

Heart/Lung disease

50.0%
(n=318)

52.5%
(n=301)

0.536

-

-

-

43.0% (n=151) /
50.8% (n=128)

0.198

55.8% (n=165) /
54.1% (n=172)

0.756

41.9%
(n=43)

39.6%
(n=48)

0.827

27.4%

-

-

33.3% (n=21) /
30.0% (n=10)

0.859

26.7% (n=15) /
35.3% (n=34)

0.562

Diabetic, 19–59 y/o

37.3%
(n=75)

29.9%
(n=87)

0.319

24.4%

-

-

28.1% (n=32) /
26.8% (n=41)

0.904

44.2% (n=43) /
32.6% (n=46)

0.266

At risk for STI

54.5%
(n=88)

46.0%
(n=126)

0.222

-

-

-

52.5% (n=61) /
50.7% (n=69)

0.845

54.2% (n=24) /
38.2% (n=55)

0.192

87.4%
(n=469)

88.4%
(n=457)

0.647

-

62.0%

52.0%

94.1% (n=221) /
94.4% (n=213)

0.912

81.5% (n=248) /
83.2% (n=244)

0.613

100%
(n=9)

90.9%
(n=11)

0.380

-

-

-

100% (n=4) /
100% (n=8)

1.000

100% (n=6) /
66% (n=3)

1.000

16.3%
(n=43)

17.0%
(n=53)

0.928

-

-

-

21.7% (n=23) /
20.0% (n=15)

0.901

10.0% (n=20) /
15.8% (n=38)

0.552

Td: >19 y/o

84.7%
(n=562)

87.0%
(n=540)

0.266

61.6%

-

-

90.8% (n=249) /
93.5% (n=231)

0.267

79.9% (n=313) /
82.2% (n=309)

0.460

MMR: >19 y/o

41.6%
(n=353)

47.0%
(n=353)

0.150

-

-

-

42.8% (n=166) /
50.3% (n=173)

0.166

40.6% (n=187) /
43.9% (n=180)

0.530

PCV13: >65 y/o

83.7%
(n=92)

90.1%
(n=81)

0.216

49.8%

49.8%

35.4%

74.1% (n=27) /
94.1% (n=17)

0.097

87.7% (n=65) /
89.1% (n=64)

0.810

P

P

PPSV23 indications

Hep B indications
Chronic liver disease

Tdap indications
19–64 y/o
Pregnantb
Other: indications
Hep A: >19 y/o

Post, postintervention; Pre, preintervention; STI, sexually transmitted infection; y/o, years old. See Box 1 for vaccine abbreviations.
Results only for patients >19 years of age (n=1105).

a

Pregnant refers only to patients at 27–36 weeks gestation.

b

Immunization rates in Milwaukee, Wisconsin, where
the study was performed, are lower than state and
national averages. However, when compared to
nationwide, Wisconsin-wide, and Milwaukee-wide
rates, immunization rates at the two clinics making
up our study setting were much higher at baseline.
These already high rates may have contributed to the
lack of response to the intervention.
Quality Improvement

Some barriers to vaccination from the patient’s
perspective include lack of caregiver knowledge,
mistrust of vaccines, and caregiver’s perceived barriers
to accessing the health care system.24-26 Barriers from
the clinician’s perspective include concerns for cost,
insurance coverage, and incorrect assumptions of
immunity.27 As an example, Tdap vaccine is not covered
by Medicare Part B unless it is part of the treatment for
www.aurora.org/jpcrr
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Table 3. Pediatric Vaccine Rates Compared to National, State, and City Rates and Further Stratified by Clinica
Clinic 1
Vaccine (Patient
Age Range)

National State
City
Data1
Data22 Data22

Pre / Post
Up-to-Date

Clinic 2
Pre / Post
Up-to-Date

Pre

Post

P

97.4%
(n=265)

98.0%
(n=244)

0.661

-

-

-

97.6% (n=164) /
98.2% (n=164)

0.703

97.0% (n=101) /
97.5% (n=80)

0.849

DTaP/Tdap
96.9%
(2 months–18 years) (n=266)

97.1%
(n=245)

0.434

-

-

-

95.7% (n=164) /
98.2% (n=164)

0.200

96.1% (n=102) /
95.1% (n=81)

0.740

Hib
(2 months–5 years)

91.9%
(n=149)

97.1%
(n=138)

0.057

-

-

-

91.1% (n=112) /
97.3% (n=111)

0.048

94.6% (n=37) /
96.3% (n=27)

0.755

Hep A
(1–18 years)

94.4%
(n=196)

95.2%
(n=187)

0.726

-

-

-

92.5% (n=107) /
96.6% (n=116)

0.184

96.6% (n=89) /
93.0% (n=71)

0.293

Hep B
(0 months–18 years)

96.7%
(n=307)

97.8%
(n=277)

0.421

-

-

-

96.0% (n=200) /
97.3% (n=186)

0.477

98.1% (n=107) /
98.9% (n=91)

0.660

Rotavirus
(2–8 months)

94.5%
(n=55)

86.4%
(n=44)

0.162

-

-

-

95.3% (n=43) /
83.3% (n=36)

0.080

91.7% (n=12) /
100% (n=8)

0.429

MMR
(2–8 months)

97.4%
(n=194)

97.3%
(n=186)

0.946

-

85.7%c 85.8%c

95.2% (n=105) /
97.4% (n=116)

0.389

100% (n=89) /
97.1% (n=70)

0.110

MenACWY
(13–18 years)

92.6%
(n=54)

97.7%
(n=44)

0.255

82.2%d

70.9%

68.6%

85.2% (n=27) /
100% (n=26)

0.042

100% (n=27) /
94.4% (n=18)

0.225

Varicella
(1–18 years)

97.1%
(n=138)

96.8%
(n=186)

0.867

-

84.1%c 84.8%c

95.2% (n=83) /
96.6% (n=116)

0.629

100% (n=55) /
97.1% (n=70)

0.209

PCV13
(2 months–18 years)b

89.3%
(n=149)

89.1%
(n=138)

0.972

-

-

-

87.5% (n=112) /
86.5% (n=111)

0.823

94.6% (n=37) /
100% (n=27)

0.226

HPV
(13–18 years)

90.7%
(n=54)

100%
(n=45)

0.036

60.4%d

53.3%

57.8%

92.6% (n=27) /
100% (n=26)

0.163

88.9% (n=27) /
100% (n=19)

0.139

Polio
(2 months–18 years)

P

P

Post, postintervention; Pre, preintervention. See Box 1 for vaccine abbreviations.
Results only for patients <19 years of age (n=584).

a

Patients 5–18 years old who were indicated for the vaccine had a high-risk indication.

b

Rate determined by 24 months of age.

c

Rate for 13–17-year-olds.

d

an injury or direct exposure to the disease.28 The MMR
vaccine rates for adults at the clinics studied were less
than 50%. MMR is possibly considered a low priority by
clinicians because individuals born in 1957 or earlier (60
years old or older at the time of this study) are considered
immune.15 Assuming that after 2022, all 19–64-yearolds will be eligible for MMR, this educational point
may need to be addressed in future interventions.
No increases in vaccination rates were observed among
refugee patients. Based on their age and risk factors,
refugee patients must be vaccinated with the following
immunizations — Polio, DTaP/DT/Td/Tdap, Hib,
Hep A, Hep B, Rotavirus, MMR, Meningococcal,
Varicella, Pneumococcal, and Influenza — before
52

JPCRR • Volume 7, Issue 1 • Winter 2020

they can submit a permanent residency application.29
These requirements could explain the clinics’ high
vaccination rates for refugee patients, which made it
harder to improve these already high rates. However,
PPSV23 immunization rates for refugees still require
much improvement. Potential explanations for the
worsened MMR#2 immunization rate postintervention
include patient refusal, shortage of the vaccine, or the
vaccine just being missed by clinic staff.
Limitations
This study was subject to several limitations. Because
Wisconsin’s immunization registry came online in
2000, information in the registry about vaccines
administered before 2000 is limited. While staff at local
Quality Improvement

Table 4. Refugee Vaccine Ratesa
Vaccine

Preintervention Postintervention

P

Polio

90.9% (n=33)

100% (n=36)

0.066

Tdap adult
(>19 y/o)

93.1% (n=58)

89.2% (n=37)

0.508

DTaP/Tdap
(<19 y/o)

91.2% (n=34)

100% (n=36)

0.070

Td

96.5% (n=57)

91.9% (n=37)

0.337

Hib

95.7% (n=23)

100% (n=24)

0.312

Hep A

73.5% (n=34)

74.2% (n=31)

0.952

Hep B

84.6% (n=52)

88.0% (n=50)

0.624

100% (n=6)

100% (n=8)

--

MMR

92.1% (n=63)

94.1% (n=51)

0.673

MMR #2

100% (n=23)

87.0% (n=23)

0.036

Meningococcal

100% (n=4)

80.0% (n=5)

0.407

Varicella

77.5% (n=40)

82.6% (n=46)

0.558

PCV13

86.2% (n=29)

92.0% (n=25)

0.509

PPSV23

37.9% (n=29)

53.3% (n=15)

0.340

Rotavirus

y/o, years old. See Box 1 for vaccine abbreviations.
Results only for refugee patients (n=171).

higher than national, Wisconsin, and Milwaukee rates,
there is still opportunity for improvement.
While a multidisciplinary team approach to this
problem is required, the development of algorithms in
electronic health records to generate patient-specific,
risk-based vaccine recommendations at the time of
a clinic visit, in addition to the age-based forecasts
available from state immunization registries, would
be helpful. However, even these interventions will
have difficulty improving the population’s overall
immunization rates if systemic factors affecting
vulnerable populations are not addressed. Therefore,
future interventions must address systemic factors in
Milwaukee, like lack of access to care, if the city is to
reach Healthy People 2020’s immunization goals.

Patient-Friendly Recap
• Compared to the general U.S. population,
immunization rates in cities often lag.

a

• The authors targeted an educational lecture
series to nurses and medical assistants in the
hope of improving vaccination rates at two
urban clinics.

health departments routinely enter into the registry
records of vaccinations administered before 2000, staff
at primary care clinics or pharmacies do not always.30
Furthermore, vaccines administered in different states
rarely make it into the registry. As a result, compared to
children, adults have less complete documentation of
vaccinations in the registry. Therefore, the up-to-date
vaccination rates in this study may be lower than actual
rates. On the other hand, because the postintervention
period spanned the flu season, the reported vaccination
rates may have skewed higher due to more focus being
placed on immunization when visits happen during the
flu season. Lastly, this study does not have the capacity
to analyze many of the systemic factors that contribute
to low immunization rates.

• While the education did not result in
substantial increases in vaccinations, this
may have been in part due to unusually high
baseline rates at the studied clinics.

CONCLUSIONS

A short-term educational program for nurses and
medical assistants at two family medicine residency
clinics did not have a significant effect in improving
most immunizations rates, likely due to the clinics’
already high age- and risk-based immunization rates.
Despite the fact that, on average, these rates were
Quality Improvement

• The authors conclude that future attempts to
improve immunization rates should go beyond
education and address systemic factors such
as access to care.
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Appendix A: Definitions for High-Risk Populations
Indication

Definition

Kidney failure

Estimated glomerular filtration rate at time of visit was <30 ml/min

Cardiac indication

If patient had any of the following:
• Any structural abnormality of the heart
• Cardiomyopathy excluding hypertension
• Any known electrocardiogram abnormalities (excluding bradycardia and tachycardia)

Pulmonary indication

If patient had any of the following:17
    • Significant structural abnormality of the lung
•C
 hronic lung disease (for asthma to be considered as a chronic lung disease, patient
had to have had a prescription for a controller medication)
•C
 urrent smoker (patients were not considered to be smokers if they used cannabis or
smokeless tobacco18)

Alcohol abuse disorder

Any patient who had a history of alcohol abuse or exceeded national drinking guidelines
was determined to have alcohol abuse disorder19

Intravenous drug use

Any patient who had a past history of intravenous drug use

Liver disease

If patient had any of the following:
• Cirrhosis
• Fatty liver disease
• Alcoholic liver disease
• Alcoholic hepatitis
• Aspartate aminotransferase or alanine aminotransferase level >2 times the upper limit of
normal (liver function tests for every patient with available results were analyzed)
• Nonalcoholic steatohepatitis
• Chronic hepatitis B
• Hepatitis C infection

High risk for sexually
If patient had any of the following:
transmitted infection (STI)
• Greater than 1 sexual partner in the past 6 months.
•E
 ver been diagnosed with an STI, including gonorrhea, chlamydia, high-risk human
papilloma virus, genital herpes, and/or human immunodeficiency virus
•H
 istory of sexual abuse, cervical cancer, and/or multiple sexual partners
•P
 atient concerned about having an STI or requesting STI screening
Refugee

a

If the patient’s chart included any of the following informationa:
•P
 atient’s primary or secondary language was listed as Karen, Burmese, Rohingya,
Arabic, Chin, Somali, or Malay
• Children who were born to refugee parents
    • Patient’s chart identified them as a refugee

Definition of refugee was chosen based on makeup of the local refugee population at large and the feasibility of coding.
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Appendix B: Quick Reference Guidea
Travelers

• Polio
• Hepatitis A
•H
 epatitis B
•M
 easles, mumps, and rubella (ensure 2 doses received)
• Meningococcal

Asplenia (sickle cell
disease)

•H
 aemophilus influenzae type B
• Meningococcal
•P
 neumococcal: PPSV23 + PCV13

Immunocompromised
individuals

•E
 x: HIV, chemotherapy, radiation therapy, high-dose steroids for >14 days
•H
 aemophilus influenzae type B
• Meningococcal
•P
 neumococcal: PPSV23 + PCV13

Men who have sex
with men

• Hepatitis A
•H
 epatitis B

History of intravenous
drug use

• Hepatitis A
•H
 epatitis B

Vaccines needed by
refugees

• Inactivated polio vaccine
• Tetanus, diphtheria, and pertussis
•H
 aemophilus influenzae type B
• Hepatitis A
•H
 epatitis B
• Rotavirus

HIV

•H
 aemophilus influenzae type B
•H
 epatitis B
•P
 neumococcal: PPSV23 + PCV13

Kidney failure

•H
 epatitis B
•P
 neumococcal: PPSV23 + PCV13

Diabetes

•H
 epatitis B
• Pneumococcal:
– Single dose of PPSV23
– If less than 18, then a dose of PCV13 also

Multiple sex partners

•H
 epatitis B

College students

•M
 easles, mumps, and rubella (ensure patient has received 2 doses)
• Meningococcal

Special points and
resources

• Any adult born in 1957 or later must have MMR vaccine documented in chart. If no
documentation of MMR, then vaccinate.
•L
 ook up vaccines that may be needed: https://www2a.cdc.gov/nip/adultimmsched/default.asp
•P
 neumococcal recommendations for adults: https://www.cdc.gov/vaccines/vpd/pneumo/
downloads/pneumo-vaccine-timing.pdf

a
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• Measles, mumps, and rubella
• Meningococcal
• Varicella
• Pneumococcal
• Seasonal influenza

For vaccine abbreviations, see Box 1 on p. 49.
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